These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2370877)

  • 1. Immunologic and clinical aspects of natural killer cells in human leukemia.
    Lotzová E; Savary CA; Pollock RE; Fuchshuber P
    Nat Immun Cell Growth Regul; 1990; 9(3):173-81. PubMed ID: 2370877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.
    Lotzová E; Savary CA; Herberman RB
    J Immunol; 1987 Apr; 138(8):2718-27. PubMed ID: 3494084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
    Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
    Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of NK cell activity from human bone marrow.
    Lotzová E; Savary CA
    J Immunol; 1987 Jul; 139(1):279-84. PubMed ID: 3495600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
    Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
    Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enrichment of oncolytic cells for adoptive therapy using centrifugal elutriation.
    Savary CA; Lotzová E; Lichtiger B; Freireich EJ
    J Clin Lab Immunol; 1990 Jul; 32(3):123-9. PubMed ID: 1966948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R; Nagler A
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human natural killer cell development from bone marrow progenitors: analysis of phenotype, cytotoxicity and growth.
    Lotzová E; Savary CA
    Nat Immun; 1993; 12(4-5):209-17. PubMed ID: 8257827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
    Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
    Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.
    Lotzová E; Savary CA; Champlin RE
    J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
    Gaddy J; Broxmeyer HE
    Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
    Arbour S; Toupin S; Bélanger R; Gyger M; Hallé JP; Perreault C; Roy DC
    Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.